Taichunamide-A Inhibits Stomach Cancer Growth Through AKT/MAPK Pathway Suppression and EGFR Inhibitor Synergy

Area of Science:

• Marine natural products
• Cancer biology
• Pharmacology

Background:

• Stomach cancer is a leading cause of cancer mortality globally, requiring new therapeutic strategies.
• Marine-derived natural products offer a promising source for novel anticancer agents.

Purpose of the Study:

• To investigate the anticancer potential of taichunamide-A (TAI-A), a marine fungal metabolite, against stomach cancer.
• To elucidate the molecular mechanisms underlying TAI-A's effects and its synergistic potential with EGFR inhibitors.

Main Methods:

• Anticancer activity was assessed using cell viability, flow cytometry, and colony formation assays in stomach cancer cell lines (AGS, HGC-27).
• Molecular mechanisms were explored via RNA sequencing, pathway analysis, qPCR, and Western blot.
• Synergistic effects with erlotinib (EGFR inhibitor) were evaluated.

Main Results:

• TAI-A exhibited potent antiproliferative activity (EC50: 0.35 μM in AGS, 0.23 μM in HGC-27) and suppressed colony formation.
• TAI-A induced apoptosis by inhibiting AKT and MAPK signaling pathways.
• Transcriptomic analysis showed downregulation of cell cycle genes and enrichment of apoptotic pathways.
• TAI-A demonstrated synergistic effects with erlotinib, enhancing apoptosis and antitumor activity.

Conclusions:

• TAI-A is a promising anticancer agent targeting multiple oncogenic pathways in stomach cancer.
• The synergistic interaction with EGFR inhibitors suggests potential for combination therapy strategies.
• Further preclinical investigation of TAI-A is warranted.